All Stories

  1. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, August 2017, Wiley

    Dr Julio Rosenstock, Carol Wysham

  2. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L tria

    Article • Diabetes Obesity and Metabolism, June 2017, Wiley

    Carol Wysham